OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

By /

OSE Immunotherapeutics SA and Boehringer Ingelheim announced a major expansion of their partnership.

Scroll to Top